Skip to main content

Ascentage Pharma Group International

Ascentage Pharma Group International is a Chinese clinical-stage biopharmaceutical enterprise headquartered in Suzhou, China, with global operations. The company specializes in the discovery, development, and commercialization of innovative targeted therapies directed at apoptosis (programmed cell death) pathways for the treatment of cancers, chronic myeloid leukemia, and hepatitis B. Principal revenue is currently earned through collaborative research licensing agreements, milestone payments, and commercial sales of approved oncology drugs. Ascentage Pharma is publicly listed on the Hong Kong Stock Exchange.

3 of the funds FundTelligence covers report a position in Ascentage Pharma Group International.

Sector
Health Care
Country
China
Funds holding it
3

Funds holding Ascentage Pharma Group International

Loading...